| Magnesium-based phosphate binder, by DOPPS country and cross-section |
| N Ptnts | Total N | Wgtd % | ||
|---|---|---|---|---|
| DOPPS Country | DOPPS Cross-section | 62 | 512 | 12.2% |
| AusNZ | D2(2002) | |||
| D3(2006) | 57 | 508 | 10.3% | |
| D3(2007) | 35 | 474 | 8.7% | |
| D4(2010) | 16 | 333 | 4.6% | |
| D4(2011) | 13 | 388 | 3.0% | |
| Belgium | D2(2002) | 0 | 536 | 0.0% |
| D3(2006) | 1 | 495 | 0.3% | |
| D3(2007) | 0 | 410 | 0.0% | |
| D4(2010) | 0 | 463 | 0.0% | |
| D4(2011) | 0 | 449 | 0.0% | |
| Canada | D2(2002) | 2 | 587 | 0.2% |
| D3(2006) | 1 | 540 | 0.2% | |
| D3(2007) | 9 | 443 | 1.4% | |
| D4(2010) | 16 | 337 | 2.9% | |
| D4(2011) | 13 | 464 | 1.8% | |
| France | D2(2002) | 18 | 506 | 3.4% |
| D3(2006) | 4 | 545 | 0.7% | |
| D3(2007) | 4 | 540 | 0.8% | |
| D4(2010) | 2 | 331 | 0.6% | |
| D4(2011) | 3 | 435 | 0.6% | |
| Germany | D2(2002) | 11 | 559 | 1.6% |
| D3(2006) | 12 | 570 | 2.3% | |
| D3(2007) | 10 | 619 | 1.5% | |
| D4(2010) | 2 | 613 | 0.2% | |
| D4(2011) | 7 | 617 | 1.0% | |
| Italy | D2(2002) | 11 | 564 | 1.9% |
| D3(2006) | 20 | 506 | 3.7% | |
| D3(2007) | 18 | 540 | 3.2% | |
| D4(2010) | 5 | 555 | 0.6% | |
| D4(2011) | 1 | 592 | 0.1% | |
| Japan | D2(2002) | 6 | 1,763 | 0.3% |
| D3(2006) | 1 | 1,820 | 0.1% | |
| D3(2007) | 0 | 1,839 | 0.0% | |
| D4(2010) | 0 | 1,678 | 0.0% | |
| D4(2011) | 0 | 1,656 | 0.0% | |
| Spain | D2(2002) | 0 | 609 | 0.0% |
| D3(2006) | 5 | 659 | 0.5% | |
| D3(2007) | 5 | 550 | 0.6% | |
| D4(2010) | 8 | 618 | 1.3% | |
| D4(2011) | 16 | 585 | 2.1% | |
| Sweden | D2(2002) | 5 | 534 | 1.2% |
| D3(2006) | 8 | 530 | 1.5% | |
| D3(2007) | 3 | 504 | 0.6% | |
| D4(2010) | 0 | 449 | 0.0% | |
| D4(2011) | 1 | 514 | 0.2% | |
| UK | D2(2002) | 6 | 552 | 1.3% |
| D3(2006) | 4 | 432 | 1.4% | |
| D3(2007) | 10 | 337 | 5.7% | |
| D4(2010) | 0 | 368 | 0.0% | |
| D4(2011) | 3 | 458 | 1.1% | |
| US | D2(2002) | 8 | 2,230 | 0.2% |
| D3(2006) | 7 | 1,791 | 0.5% | |
| D3(2007) | 0 | 1,308 | 0.0% | |
| D4(2010) | 43 | 3,422 | 0.9% | |
| D4(2011) | 31 | 3,829 | 0.4% | |
| Medications reported as prescribed (not necessarily taken) in previous week (D2-D3) or end of study month (D4), among all patients |
Please see additional methodological information in the Data Sources and Methods section.